Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.73USD
15 Jan 2019
Change (% chg)

$0.36 (+0.85%)
Prev Close
$42.37
Open
$42.61
Day's High
$43.24
Day's Low
$42.43
Volume
8,470,941
Avg. Vol
7,360,126
52-wk High
$46.46
52-wk Low
$33.20

Latest Key Developments (Source: Significant Developments)

Pfizer's Aurangabad And IKKT Sites In India Will Immediately Cease Manufacturing
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Pfizer Inc ::PFIZER INC - PFIZER HAS CONDUCTED A THOROUGH EVALUATION OF THE IKKT AND AURANGABAD SITES IN INDIA.PFIZER INC - BOTH THE AURANGABAD AND IKKT SITES TO IMMEDIATELY CEASE MANUFACTURING WITH INTENTION TO EXIT BOTH SITES AS SOON AS POSSIBLE IN 2019.PFIZER INC - IKKT CURRENTLY EMPLOYS APPROXIMATELY 1,000 COLLEAGUES DIRECTLY AND AURANGABAD SITE EMPLOYS APPROXIMATELY 700 COLLEAGUES..PFIZER SAYS CONCLUDED THAT DUE TO THE VERY SIGNIFICANT LONG TERM LOSS OF PRODUCT DEMAND, MANUFACTURING AT IKKT AND AURANGABAD SITES IS NOT VIABLE.PFIZER - VIZAG SITE IS NOW EXPANDED INTO A GLOBAL TERMINALLY STERILIZED MANUFACTURING CENTER OF EXCELLENCE.PFIZER SAYS MOST OF PRODUCTS MANUFACTURED AT IKKT AND AURANGABAD SITES IN INDIA WILL BE DISCONTINUED NOW.  Full Article

Cytoreason Signs Collaboration Agreement With Pfizer Inc
Monday, 7 Jan 2019 

Jan 7 (Reuters) - CYTOREASON::CYTOREASON SIGNS COLLABORATION AGREEMENT WITH PFIZER INC. TO UTILIZE CYTOREASON'S MACHINE LEARNING MODEL OF IMMUNE SYSTEM FOR DRUG DISCOVERY.CYTOREASON SAYS WILL RECEIVE FROM PFIZER PAYMENTS POTENTIALLY EQUALING UP TO LOW DOUBLE DIGIT MILLIONS OF US$.  Full Article

Canada Completes Abuse Of Dominance Investigation Into Practices Of Celgene, Pfizer And Sanofi
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Celgene Corp ::COMPETITION BUREAU COMPLETES ABUSE OF DOMINANCE INVESTIGATION INTO PRACTICES OF CELGENE, PFIZER AND SANOFI.COMPETITION BUREAU OF CANADA - INSUFFICIENT EVIDENCE TO SHOW COMPETITION SUBSTANTIALLY LESSENED/PREVENTED IN INVESTIGATION INTO CELGENE, PFIZER, SANOFI.COMPETITION BUREAU OF CANADA - BUREAU IS UNABLE TO CONCLUDE THAT COMPETITION ACT HAS BEEN CONTRAVENED.  Full Article

Astellas And Pfizer Announce Positive Top-Line Results From Phase 3 Arches Trial Of Xtandi
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Pfizer Inc ::ASTELLAS AND PFIZER ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 ARCHES TRIAL OF XTANDI® (ENZALUTAMIDE) IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.ASTELLAS AND PFIZER ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 ARCHES TRIAL OF XTANDI® (ENZALUTAMIDE) IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.PFIZER INC - PHASE 3 ARCHES TRIAL MET ITS PRIMARY ENDPOINT.PFIZER INC - PRELIMINARY SAFETY ANALYSIS OF ARCHES TRIAL APPEARS CONSISTENT WITH SAFETY PROFILE OF XTANDI IN PREVIOUS CLINICAL TRIALS.PFIZER - RESULTS FROM ARCHES DEMONSTRATE STATISTICALLY SIGNIFICANT IMPROVEMENT IN MARKER OF DISEASE PROGRESSION, RADIOGRAPHIC PROGRESSION-FREE SURVIVAL.  Full Article

Kineta Enters Research Collaboration And License Agreement With Pfizer
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Pfizer Inc ::KINETA ENTERS RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER TO DEVELOP NEW CANCER IMMUNOTHERAPIES.PFIZER INC - KINETA IMMUNO-ONCOLOGY TO RECEIVE $15 MILLION UPFRONT.PFIZER INC - KIO WILL BE ELIGIBLE TO RECEIVE UP TO $505 MILLION IN POTENTIAL RESEARCH DEVELOPMENT AND SALES MILESTONE PAYMENTS.PFIZER INC - PFIZER WILL FUND RIG-I TARGET-RELATED RESEARCH CONDUCTED BY KINETA FOR INITIAL PERIOD OF 3 YEARS.PFIZER INC - KIO IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES ON NET SALES.  Full Article

Pfizer Raises Dividend 6 Pct, Authorizes New $10 Bln Share Repurchase Program
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Pfizer Inc ::DECLARES FIRST-QUARTER 2019 DIVIDEND.AUTHORIZES NEW $10 BILLION SHARE REPURCHASE PROGRAM.INCREASES QUARTERLY DIVIDEND BY 6 PERCENT TO $0.36 PER SHARE.NEW PROGRAM IS IN ADDITION TO $4.9 BILLION REMAINING UNDER COMPANY'S CURRENT AUTHORIZATION.  Full Article

UK's CMA Decides Not To Refer Baxter-Hospira Deal To Phase 2 Investigation
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - UK's Competition and Markets Authority (CMA)::DECIDED NOT TO REFER BAXTER INTERNATIONAL-HOSPIRA UK DEAL TO PHASE 2 INVESTIGATION UNDER PROVISIONS OF ENTERPRISE ACT 2002.  Full Article

Abbvie Announces Humira Global Patent License With Pfizer
Friday, 30 Nov 2018 

Nov 30 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES HUMIRA (ADALIMUMAB) GLOBAL PATENT LICENSE WITH PFIZER.PFIZER WILL PAY ROYALTIES TO ABBVIE FOR LICENSING ITS HUMIRA PATENTS AND ACKNOWLEDGES VALIDITY OF LICENSED PATENTS.ABBVIE WILL MAKE NO PAYMENTS TO PFIZER.WILL GRANT PFIZER A NON-EXCLUSIVE LICENSE ON SPECIFIED DATES TO ABBVIE'S INTELLECTUAL PROPERTY RELATING TO HUMIRA.  Full Article

Pfizer Reaches A Global Agreement With AbbVie
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Pfizer Inc ::PFIZER REACHES A GLOBAL AGREEMENT WITH ABBVIE.ALL INTELLECTUAL PROPERTY MATTERS FOR PFIZER'S PROPOSED ADALIMUMAB BIOSIMILAR RESOLVED.IN UNITED STATES, LICENSE PERIOD WILL BEGIN ON NOVEMBER 20, 2023.ALL LITIGATION PENDING BETWEEN PARTIES WILL BE WITHDRAWN.FINANCIAL DETAILS OF AGREEMENTS ARE CONFIDENTIAL..PFIZER MAY LAUNCH ITS ADALIMUMAB BIOSIMILAR UPON APPROVAL BY EUROPEAN MEDICINES AGENCY IN EUROPE.ABBVIE GRANTS CO A NON-EXCLUSIVE PATENT LICENSE FOR USE AND SALE OF CO'S PROPOSED ADALIMUMAB BIOSIMILAR FOR MANY COUNTRIES AROUND WORLD.SIGNED LICENSING AGREEMENTS WITH ABBVIE.  Full Article

Jianke.Com Enters Into Strategic Cooperation With Pfizer
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Pfizer Inc ::JIANKE.COM ENTERS INTO STRATEGIC COOPERATION WITH PFIZER.  Full Article